Germany
Atriva Therapeutics GmbH: Atriva Therapeutics is a clinical-stage biopharmaceutical company headquartered in Germany with a mission to develop an antiviral therapy platform targeting severe respiratory and systemic diseases induced by RNA viruses, including influenza and COVID-19. The company's lead product, zapnometinib (ATR-002), is a first-in-class, host-targeting agent designed to inhibit viral replication and modulate the body’s immune response to RNA viruses. Atriva was founded in 2015 in Tübingen by a team of leading scientists in viral research and industry experts.
As a founding member of the BEAT-COV initiative, Atriva is pioneering the development of host-targeting antiviral therapies to mitigate viral resistance and contribute to pandemic preparedness. Their innovative approach has attracted €8.60M in debt financing investment from Meneldor and HTGF | High-Tech Gruenderfonds as of August 12, 2020.
With a focus on biopharma, biotechnology, and pharmaceutical industries, Atriva Therapeutics is paving the way for antiviral drug innovation, addressing critical unmet medical needs and making significant contributions to the global healthcare landscape. For more information, visit www.atriva-therapeutics.com and connect on LinkedIn and Twitter (@AtrivaTx).
